Cargando…

The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease

Background: Irrreversible interstitial lung disease (ILD) is associated with high morbidity and mortality. Palliative care needs of patients and caregivers are not routinely assessed; there is no tool to identify needs and triage support in clinical practice. Objective: The study objective was to ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boland, Jason W., Reigada, Carla, Yorke, Janelle, Hart, Simon P., Bajwah, Sabrina, Ross, Joy, Wells, Athol, Papadopoulos, Athanasios, Currow, David C., Grande, Gunn, Macleod, Una, Johnson, Miriam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2016
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860674/ https://www.ncbi.nlm.nih.gov/pubmed/26840603 http://dx.doi.org/10.1089/jpm.2015.0355

Ejemplares similares

Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease
por: Johnson, Miriam J, et al.
Publicado: (2018)

Implementation of the Needs Assessment Tool for patients with interstitial lung disease (NAT:ILD): facilitators and barriers
por: Reigada, C, et al.
Publicado: (2017)

Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review
por: Carvajalino, Sabrina, et al.
Publicado: (2018)

Indications and patterns of use of benzodiazepines and opioids in severe interstitial lung disease: a population-based longitudinal study
por: Genberg, Jenny, et al.
Publicado: (2021)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis
por: Bajwah, Sabrina, et al.
Publicado: (2021)

Comorbidities in interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2017)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2019)

Smoking and interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2015)

The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
por: Brown, Kevin K., et al.
Publicado: (2020)

Interstitial Lung Abnormalities: An Evolving Entity
por: Tomassetti, Sara, et al.
Publicado: (2022)

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Kokosi, Maria A., et al.
Publicado: (2018)

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)
por: Higginson, Irene J, et al.
Publicado: (2020)

Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges
por: Kewalramani, Namrata, et al.
Publicado: (2022)

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives
por: Tomassetti, Sara, et al.
Publicado: (2022)

The 6-min walk test as a primary end-point in interstitial lung disease
por: Harari, Sergio, et al.
Publicado: (2022)

Family Caregivers Who Would Be Unwilling to Provide Care at the End of Life Again: Findings from the Health Survey for England Population Survey
por: Johnson, Miriam J., et al.
Publicado: (2016)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Interstitial pneumonia with autoimmune features: challenges and controversies
por: Mackintosh, John A., et al.
Publicado: (2021)

Cancer-related information needs and treatment decision-making experiences of people with dementia in England: a multiple perspective qualitative study
por: McWilliams, Lorna, et al.
Publicado: (2018)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2018)

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
por: Khanna, Dinesh, et al.
Publicado: (2015)

Before Freezing Out Cryobiopsy, We Need to Thaw Out Flaws in the Diagnosis of Interstitial Lung Disease
por: Maldonado, Fabien, et al.
Publicado: (2019)

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease
por: Jacob, Joseph, et al.
Publicado: (2018)

The detection, assessment and clinical evolution of interstitial lung abnormalities identified through lung cancer screening
por: Balata, Haval, et al.
Publicado: (2023)

An integrated understanding of the complex drivers of emergency presentations and admissions in cancer patients: Qualitative modelling of secondary-care health professionals’ experiences and views
por: Chen, Hong, et al.
Publicado: (2019)

Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study
por: Jacob, Joseph, et al.
Publicado: (2016)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
por: Saunders, Peter, et al.
Publicado: (2017)

Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Funke-Chambour, Manuela, et al.
Publicado: (2022)

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial
por: Denton, Christopher P, et al.
Publicado: (2022)

Predicting outcomes in rheumatoid arthritis related interstitial lung disease
por: Jacob, Joseph, et al.
Publicado: (2019)

Non-specific interstitial pneumonia in cigarette smokers: a CT study
por: Marten, Katharina, et al.
Publicado: (2009)

Evaluation of inter-observer variation for computed tomography identification of childhood interstitial lung disease
por: Jacob, Joseph, et al.
Publicado: (2019)

Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?
por: Chaudhuri, Nazia, et al.
Publicado: (2021)

Residual Lung Disease at 6-month Follow-up CT after COVID-19: Clinical Significance Is a Key Issue
por: Wells, Athol U, et al.
Publicado: (2021)

Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement
por: Aronson, Kerri I., et al.
Publicado: (2021)

A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease
por: Bax, Simon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5425on3590fhrpvh0u7c4lmma2